Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.47 |
| ▸ | HTR3B | O95264 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24017152 | 0.83 | PNMT (0.74) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL24017049 | 0.83 | PNMT (0.74) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL1570139 | 0.82 | PNMT (0.71) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL266685 | 0.82 | PNMT (1.00) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL14478283 | 0.82 | PNMT (1.00) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL3335737 | 0.82 | PNMT (0.60) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL30363681 | 0.82 | PNMT (1.00) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL8153800 | 0.80 | PNMT (0.69) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL7489958 | 0.80 | PNMT (0.69) | PNMTTAAR1IDO1CYP3A4AGXT | |
| SCHEMBL1570196 | 0.80 | PNMT (0.69) | PNMTTAAR1IDO1CYP3A4AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | claimed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | claimed |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-01-12 | — | — | US | claimed |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-02-13 | — | — | US | claimed |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-06-11 | — | — | US | claimed |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-03-29 | — | — | US | claimed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | claimed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | claimed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | claimed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | claimed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | claimed |
| EP-4395763-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023034944-A1 | METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE | AXSOME THERAPEUTICS (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS., LTD. | 2021-04-22 | — | — | US | disclosed |
| EP-3110792-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK Biopharmaceuticals Co., Ltd. (KR) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. | 2016-10-20 | — | — | US | disclosed |
| US-9403761-B2 | Aminocarbonylcarbamate compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-08-02 | — | — | US | disclosed |
| WO-2015130121-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | WO | disclosed |
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246874-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-10888542-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-20160303067-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-20180085337-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-20210113514-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-20200046674-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-20230218562-A1 | AMINOCARBONYLCARBAMATE COMPOUNDS | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
| US-10314808-B2 | Aminocarbonylcarbamate compounds | SLC6A3, SLC6A2, SLC6A4 | PNMT 496/4885TAAR1 79/4885IDO1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.